Zacks restated their hold rating on shares
of Globus Medical (NASDAQ:GMED) in a report released on Friday.
Zacks’ analyst wrote, “Globus Medical, Inc. is a medical device company focused on the design, development and commercialization of products that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: innovative fusion or disruptive technologies. Its innovative fusion products address a broad range of spinal fusion surgical procedures. Its disruptive technology products include minimally invasive surgical, motion preservation and advanced biomaterials technologies. Globus Medical, Inc. is based in Audubon, Pennsylvania. “
Globus Medical (NASDAQ:GMED) traded down 2.47% on Friday, hitting $23.30. 984,178 shares of the company’s stock traded hands. Globus Medical has a 1-year low of $17.45 and a 1-year high of $26.07. The stock’s 50-day moving average is $24. and its 200-day moving average is $23.. The company has a market cap of $2.21 billion and a price-to-earnings ratio of 24.02.
Globus Medical (NASDAQ:GMED) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.25 by $0.05. The company had revenue of $128.80 million for the quarter, compared to the consensus estimate of $127.77 million. Analysts expect that Globus Medical will post $1.02 EPS for the current fiscal year.
